<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2696-130X</journal-id>
<journal-title><![CDATA[Revista mexicana de angiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. angiol.]]></abbrev-journal-title>
<issn>2696-130X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Angiología, Cirugía Vascular y Endovascular A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2696-130X2023000300085</article-id>
<article-id pub-id-type="doi">10.24875/rma.23000019</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efecto del tratamiento combinado de estatinas y evolocumab en pacientes con enfermedad arterial periférica]]></article-title>
<article-title xml:lang="en"><![CDATA[Effect of combined treatment of statins and evolocumab in patients with peripheral arterial disease]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Olivares-García]]></surname>
<given-names><![CDATA[Jorge D.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Román-Hernández]]></surname>
<given-names><![CDATA[Rigoberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Meráz-Martínez]]></surname>
<given-names><![CDATA[Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Central Militar Departamento de Cirugía Vascular ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Politécnico Nacional Escuela Superior de Medicina Sección de Estudios de Posgrado e Investigación]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2023</year>
</pub-date>
<volume>51</volume>
<numero>3</numero>
<fpage>85</fpage>
<lpage>92</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2696-130X2023000300085&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2696-130X2023000300085&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2696-130X2023000300085&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: La ateroesclerosis se caracteriza por el depósito de colesterol y endurecimiento del endotelio. El evolocumab es un anticuerpo monoclonal que inhibe la PCSK9 y estabiliza la placa ateromatosa.  Objetivo: Evaluar el efecto del evolocumab en conjunto con estatinas en pacientes con enfermedad arterial periférica (EAP).  Métodos: Estudio observacional de cohorte prospectiva; se incluyeron 303 pacientes con EAP en claudicación con tratamiento de estatinas y evolocumab monoterapia con estatinas durante un periodo de 6 meses, de julio 2021 a julio 2022. Se obtuvieron las mediciones basal y final del estudio de los niveles séricos de LDL, el porcentaje de estenosis arterial mediante ultrasonido doppler, el índice tobillo-brazo y claudicación. Se realizaron pruebas de Kruskal-Wallis y de U de Mann-Whitney.  Resultados: El tratamiento combinado redujo el porcentaje de estenosis arterial en las ramas femorales, tibiales y peroneas (p &lt; 0.05) así como en los niveles de LDL (p &lt; 0.0001) y los pacientes reportaron 50% menos claudicación.  Conclusiones: En nuestro estudio el tratamiento de evolocumab y estatinas disminuyó la estenosis arterial y la claudicación de pacientes con EAP.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Atherosclerosis is characterized by the deposition of cholesterol and hardening of the endothelium. Evolocumab is a monoclonal antibody that inhibits PCSK9 and stabilizes the atheromatous plaque.  Objective: To evaluate the effect of evolocumab and statins on peripheral arterial disease (PAD).  Methods: A prospective observational cohort study that included 303 patients with PAD in claudication treated with statins and evolocumab and evolocumab, compared to monotherapy with statins, during a period of six months, from July 2021 to July 2022. Baseline and final measurements of serum LDL levels, the percentage of arterial stenosis by arterial Doppler ultrasound, the ankle-brachial index and claudication were obtained. Kruskal-Wallis and Mann-Whitney U tests were performed.  Results: The combined treatment reduced the percentage of arterial stenosis in the femoral, tibial, and peroneal branches (p &lt; 0.05) as well as in LDL levels (p &lt; 0.0001) and reported 50% less claudication.  Conclusions: In our study, the treatment with evolocumab and statins decreased arterial stenosis and claudication in patients with PAD.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Enfermedad arterial periférica]]></kwd>
<kwd lng="es"><![CDATA[Aterosclerosis]]></kwd>
<kwd lng="es"><![CDATA[Claudicación]]></kwd>
<kwd lng="es"><![CDATA[Inhibidores de PCSK9]]></kwd>
<kwd lng="es"><![CDATA[Evolocumab]]></kwd>
<kwd lng="en"><![CDATA[Peripheral artery disease]]></kwd>
<kwd lng="en"><![CDATA[Atherosclerosis]]></kwd>
<kwd lng="en"><![CDATA[Claudication]]></kwd>
<kwd lng="en"><![CDATA[PCSK9 inhibitors]]></kwd>
<kwd lng="en"><![CDATA[Evolocumab]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alloubani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nimer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Samara]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relationship between hyperlipidemia, cardiovascular disease and stroke:A systematic review]]></article-title>
<source><![CDATA[Curr Cardiol Rev]]></source>
<year>2021</year>
<volume>17</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Miranda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pedro-Botet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dianas terapéuticas en el tratamiento de las dislipemias:de las estatinas a los inhibidores de PCSK9. Necesidades no cubiertas]]></article-title>
<source><![CDATA[Clínica e Investigación en Arteriosclerosis]]></source>
<year>2021</year>
<volume>33</volume>
<page-range>46-52</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferket]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Spronk]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Colkesen]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[Hunink]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic review of guidelines on peripheral artery disease screening]]></article-title>
<source><![CDATA[American J Med]]></source>
<year>2012</year>
<volume>125</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>198-208</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ference]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Ginsberg]]></surname>
<given-names><![CDATA[HN]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ray]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Packard]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bruckert]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low-density lipoproteins cause atherosclerotic cardiovascular disease 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2017</year>
<volume>38</volume>
<page-range>2459-72</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bea]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Civeira]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Jarauta]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lamiquiz-Moneo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Calahorra]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Marco-Benedí]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Asociación de la presencia de placa carotídea en la aparición de eventos cardiovasculares en pacientes con hipercolesterolemias genéticas]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2017</year>
<volume>70</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>551-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mazhar]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Haider]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors:An emerging new therapeutic option for the treatment of dyslipidemia]]></article-title>
<source><![CDATA[J Pharmacol Pharmacother]]></source>
<year>2016</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>190</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Navarese]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Ko&#322;odziejczak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schulze]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gurbel]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Tantry]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2015</year>
<volume>163</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>40-51</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cuevas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Indicaciones para el uso de los inhibidores de la PCSK9]]></article-title>
<source><![CDATA[Rev Colomb Cardiol]]></source>
<year>2017</year>
<volume>24</volume>
<page-range>19-24</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Nedergaard]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fialkow]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Neutel]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Ramstad]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL lowering in patients with hypercholesterolemia:the LAPLACE-2 randomized clinical trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2014</year>
<volume>311</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1870-83</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shapiro]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Tavori]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Fazio]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PCSK9:from basic science discoveries to clinical trials]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2018</year>
<volume>122</volume>
<page-range>1420-38</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonaca]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Nault]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Giugliano]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Keech]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Pineda]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Kanevsky]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease:Insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2018</year>
<volume>137</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>338-50</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mostaza]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Puras]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Blasco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lahoz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Samaniego]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilización de tratamientos cardiovasculares preventivos y consecución de objetivos terapéuticos en pacientes con enfermedad arterial periférica]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2012</year>
<volume>65</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>713-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García García]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz Batista]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arpajón Peña]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Estévez Perera]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aldama Figueroa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Conesa González]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfermedad arterial periférica asintomática en pacientes con factores de riesgo del síndrome metabólico]]></article-title>
<source><![CDATA[Rev Cubana Angiol Cir Vasc]]></source>
<year>2018</year>
<volume>19</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>91-103</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toth]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Banach]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statins:Then and now]]></article-title>
<source><![CDATA[Methodist Debakey Cardiovasc J]]></source>
<year>2019</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>23-31</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrios]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Escobar]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Arrarte]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Roldán]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primer registro nacional de evolocumab en la práctica clínica en unidades de cardiología en España. Estudio RETOSS-CARDIO]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2020</year>
<volume>73</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>513-5</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[GG]]></given-names>
</name>
<name>
<surname><![CDATA[Gabriel Steg]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bhatt]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Bittner]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Goodman]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical efficacy and safety of alirocumab after acute coronary syndrome according to achieved level of low-density lipoprotein cholesterol:A Propensity score-matched analysis of the ODYSSEY OUTCOMES trial]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2021</year>
<volume>143</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1109-22</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Sendón]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dalmau]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Una historia resumida. La inhibición de la PCSK9 y su desarrollo clínico]]></article-title>
<source><![CDATA[Rev Esp Cardiol Supl]]></source>
<year>2017</year>
<volume>17</volume>
<page-range>10-5</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Philadelpho]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Souza]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Souza]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Santiago]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IAF, QGF, and QDF peptides exhibit cholesterol-lowering activity through a statin-like HMG-CoA reductase regulation mechanism:In silico and in vitro approach]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2021</year>
<volume>22</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>11067</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ginsberg]]></surname>
<given-names><![CDATA[HN]]></given-names>
</name>
<name>
<surname><![CDATA[Farnier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Sattar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Baccara-Dinet]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of alirocumab in individuals with diabetes mellitus:Pooled analyses from five placebo-controlled phase 3 studies]]></article-title>
<source><![CDATA[Diabetes Ther]]></source>
<year>2018</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>131734</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallego-Colon]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Daum]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yosefy]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statins and PCSK9 inhibitors:A new lipid-lowering therapy]]></article-title>
<source><![CDATA[Eur J Pharmacol]]></source>
<year>2020</year>
<volume>878</volume>
<page-range>173114</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giugliano]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Pedersen]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[De Ferrari]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Gaciong]]></surname>
<given-names><![CDATA[ZA]]></given-names>
</name>
<name>
<surname><![CDATA[Ceska]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor Evolocumab:a prespecified secondary analysis of the FOURIER trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2017</year>
<volume>390</volume>
<numero>10106</numero>
<issue>10106</issue>
<page-range>1962-71</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
